Should we start all patients with diabetic retinopathy on fenofibrates? - Wikidata - awgldk - TriplyDB

Should we start all patients with diabetic retinopathy on fenofibrates?

Should we start all patients with diabetic retinopathy on fenofibrates?

http://www.wikidata.org/entity/Q37346390

about

Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets

P2860

Q27014620-84435665-B227-4CF2-869E-DB45408DDA41

P2860

Should we start all patients with diabetic retinopathy on fenofibrates?

http://www.wikidata.org/entity/Q37346390

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Should we start all patients with diabetic retinopathy on fenofibrates?

@en

Should we start all patients with diabetic retinopathy on fenofibrates?

@nl

type

label

Should we start all patients with diabetic retinopathy on fenofibrates?

@en

Should we start all patients with diabetic retinopathy on fenofibrates?

@nl

prefLabel

Should we start all patients with diabetic retinopathy on fenofibrates?

@en

Should we start all patients with diabetic retinopathy on fenofibrates?

@nl

P1433

Q37346390-2DD84AD0-E781-47E7-B2A5-7A65C11E0F90

P1476

Q37346390-89438E97-AE97-449D-8F30-B64154D73E0C

P2093

Q37346390-436FFE6E-2FC4-485E-B403-F164DD4532AC

Q37346390-7D6670CA-AFD3-4D9C-BEDA-2D68AA51CE03

Q37346390-99D3A414-B0AE-4BDC-AD72-28129A47E47E

Q37346390-DD9372AF-F7CB-4EF7-B3EF-B84ABAA2C454

Q37346390-FEEB54BB-9CBC-4FB8-9F9D-26B791EBBA16

P275

Q37346390-F8CE4BDE-D03F-4528-B579-443EBAB580E2

P2860

Q37346390-01EE8DB0-0C50-4714-AC80-4A8017A65271

Q37346390-06889F5E-C894-4376-9D94-60204908F36E

Q37346390-0E04A831-5F05-4488-A1F2-07071D81BA83

Q37346390-13AA65D3-3EBC-4F54-9786-6173FAB89B13

Q37346390-1B641493-5CF4-4AE7-9CCC-EEC4D469437C

Q37346390-2B109B50-71A1-4A2A-A3A1-378E5E6D3DC8

Q37346390-302419DD-A5B5-4832-95B2-BE58243A1515

Q37346390-3CC875EB-1528-4D2A-84D0-47066B484826

Q37346390-543CD32C-491D-45A8-BC65-8EAF4F67926B

Q37346390-5761791F-7B9B-4FAA-B318-BF4BCA942EF9

P304

Q37346390-F6E0D9EA-7857-4517-A58A-F466A4CA6F78

P31

Q37346390-52CB4489-4549-4371-92FE-191B6301C779

Q37346390-77A39079-A1AC-4279-B310-47D0A6EF117E

P356

Q37346390-C835F3B5-6B78-4E2C-859E-ED09BA80427A

P407

Q37346390-6D6550F4-0261-4031-9C94-9A50878CD0FA

P433

Q37346390-BD7ADFF0-8B25-455C-A44C-FA4D1F3032B7

P478

Q37346390-C86209D1-B8EB-46B5-AE7C-199BE7779EE1

P5008

Q37346390-EB839FCF-7458-4CCA-AB98-8B3B1A497C3A

P577

Q37346390-F7937F32-4C8A-4F8A-8E64-8B165C8E342D

P698

Q37346390-F64E7C4D-9BF8-4CAE-9A58-AB736B08C52C

P921

Q37346390-4623D96C-A058-4AB4-BC81-7095C4C23318

Q37346390-9355CD42-04D2-4BCA-8540-D6CF4070F988

Q37346390-C3672F15-1ECE-4D5B-842A-1C85F58397BC

P932

Q37346390-EF571222-238C-4059-B738-B32FEF7AA15A

P356

0974-9233.120012

P1433

Middle East African Journal of Ophthalmology

P1476

Should we start all patients with diabetic retinopathy on fenofibrates?

@en

P2093

Gurvinder Kaur

http://www.w3.org/2001/XMLSchema#string

Jacob Koshy

http://www.w3.org/2001/XMLSchema#string

Jency M Koshy

http://www.w3.org/2001/XMLSchema#string

Satish Thomas

http://www.w3.org/2001/XMLSchema#string

Thomas Mathew

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

Retinopathy and microalbuminuria in type II diabetic patients

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Fenofibrate - a potential systemic treatment for diabetic retinopathy?

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Effects of intensive glucose lowering in type 2 diabetes

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

P304

309-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0974-9233.120012

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24339680

http://www.w3.org/2001/XMLSchema#string

P921

diabetic retinopathy

P932

3841948

http://www.w3.org/2001/XMLSchema#string